News

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines
Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...
Revolution Medicines’ Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the most promising stocks according to Wall Street analysts. On June 23, ...
Taiwan News1d
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which was filed with the Securities and Exchange Commission ...
Precision Medicine Online1d
Verastem KRAS-Mutant Ovarian Cancer Treatment Activity Affirmed in Investigator-Initiated Study
Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...
Pharmabiz1d
HotSpot presents preclinical data from small molecule CBM signalosome inhibitor programme at ESMO Gastrointestinal Cancers Congress 2025
In combination with a KRAS inhibitor, HotSpot’s CBM signalosome inhibitor achieved complete suppression of downstream signalling in KRASG12X cell lines. HotSpot’s CBM signalosome inhibitor ...
New Cancer Drug Blocks Tumors Without Debilitating Side Effects
A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.
GEN - Genetic Engineering and Biotechnology News2d
Therapeutic Candidates for Difficult Targets Emerge
Recent developments in protein-protein interactions (PPI) give hope for patients with advanced or untreatable diseases.
TMCnet2d
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER
Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults - KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel ...
Becoming an ‘Accredited Investor’ opens multiple investment opportunities, but very few know about it
SEBI's accredited investor framework, introduced in 2021, aims to provide sophisticated investors with access to exclusive ...
BrightSpring’s Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies
BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that ...